Evaluation of Clinical Meaningfulness of Red Clover ( Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Wiesław Kanadys, Agnieszka Barańska, Agata Błaszczuk, Małgorzata Polz-Dacewicz, Bartłomiej Drop, Krzysztof Kanecki, Maria Malm, Wiesław Kanadys, Agnieszka Barańska, Agata Błaszczuk, Małgorzata Polz-Dacewicz, Bartłomiej Drop, Krzysztof Kanecki, Maria Malm

Abstract

The meta-analysis presented in this article covered the efficacy of red clover isoflavones in relieving hot flushes and menopausal symptoms in perimenopausal and postmenopausal women. Studies were identified by MEDLINE (PubMed), Embase, and the Cochrane Library searches. The quality of the studies was evaluated according to Cochrane criteria. A meta-analysis of eight trials (ten comparisons) demonstrated a statistically significant reduction in the daily incidence of hot flushes in women receiving red clover compared to those receiving placebo: weighted mean difference (WMD-weighted mean difference) -1.73 hot flushes per day, 95% CI (confidence interval) -3.28 to -0.18; p = 0.0292. Due to 87.34% homogeneity, the performed analysis showed substantive difference in comparisons of postmenopausal women with ≥5 hot flushes per day, when the follow-up period was 12 weeks, with an isoflavone dose of ≥80 mg/day, and when the formulations contained a higher proportion of biochanin A. The meta-analysis of included studies assessing the effect of red clover isoflavone extract on menopausal symptoms showed a statistically moderate relationship with the reduction in the daily frequency of hot flushes. However, further well-designed studies are required to confirm the present findings and to finally determine the effects of red clover on the relief of flushing episodes.

Keywords: Trifolium pratense; hot flushes; isoflavones; menopausal symptoms; perimenopausal women; postmenopausal women; red clover.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the selection procedure for studies included in the current review regarding red clover in menopausal symptoms. Abbreviations: RCTs, randomized controlled trials.
Figure 2
Figure 2
Risk of bias summary for each study as assessed by the authors [33,34,35,36,37,38,39,40,41,42,43,44].
Figure 3
Figure 3
The assessment of risk of bias for each item; data are shown as a percentage for trials.
Figure 4
Figure 4
Effects of isoflavones with red clover (Trifolium pratense) vs. placebo on the daily frequency of hot flushes in peri- and post-menopausal women. Number in brackets following author’s name refers to dose of isoflavones in the study with more than one active group [33,34,35,36,37,38,41,44]. Abbreviations: RCIE, red clover isoflavone extract; WMD, weighted mean difference.
Figure 5
Figure 5
Effects of red clover (Trifolium pratense) isoflavones vs. placebo on rating menopausal symptoms using the following questionnaires, based on the respondents’ replies concerning the intensity of complaints. Number in brackets following author’s name refers to the dose of isoflavones in the study with more than one active group [33,34,36,38,39,40,41,42,43,44]. The letter A marks the first part of the figure containing the Kupperman Menopausal Index analysis. The letter B marks the second part of the figure containing the Greene Climacteric Scale analysis. The letter C marks the third part of the figure containing the Menopause Rating Scale analysis. Abbreviations: WMD, weighted mean difference.

References

    1. Thurston R.C. Vasomotor symptoms: Natural history, physiology, and links with cardiovascular health. Climacteric. 2018;21:96–100. doi: 10.1080/13697137.2018.1430131.
    1. Monteleone P., Mascagni G., Giannini A., Genazzani A.R., Simoncini T. Symptoms of menopause—Global prevalence, physiology and implications. Nat. Rev. Endocrinol. 2018;14:199–215. doi: 10.1038/nrendo.2017.180.
    1. Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B., Hess R., Joffe H., Kravitz H.M., Tepper P.G., et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern. Med. 2015;175:531–539. doi: 10.1001/jamainternmed.2014.8063.
    1. Freeman E.W., Sherif K. Prevalence of hot flushes and night sweats around the world: A systematic review. Climacteric. 2007;10:197–214. doi: 10.1080/13697130601181486.
    1. Gold E.B., Colvin A., Avis N., Bromberger J., Greendale G.A., Powell L., Sternfeld B., Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of women’s health across the nation. Am. J. Public Health. 2006;96:1226–1235. doi: 10.2105/AJPH.2005.066936.
    1. Duffy O.K., Iversen L., Hannaford P.C. Factors associated with reporting classic menopausal symptoms differ. Climacteric. 2013;16:240–251. doi: 10.3109/13697137.2012.697227.
    1. Herber-Gast G.-C.M., Mishra G.D., van der Schouw Y.T., Brown W.J., Dobson A.J. Risk factors for night sweats and hot flushes in midlife: Results from a prospective cohort study. Menopause. 2013;20:953–959. doi: 10.1097/GME.0b013e3182844a7c.
    1. Chung H.-F., Pandeya N., Dobson A.J., Kuh D., Brunner E.J., Crawford S.L., Avis N.E., Gold E.B., Mitchell E.S., Woods N.F., et al. The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: An international pooled analysis of eight studies in the InterLACE consortium. Psychol. Med. 2018;48:2550–2561. doi: 10.1017/S0033291718000168.
    1. Geukes M., van Aalst M.P., Robroek S.J., Laven J.S.E., Oosterhof H. The impact of menopause on work ability in women with severe menopausal symptoms. Maturitas. 2016;90:3–8. doi: 10.1016/j.maturitas.2016.05.001.
    1. Rossmanith W.G., Ruebberdt W. What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol. Endocrinol. 2009;25:303–314. doi: 10.1080/09513590802632514.
    1. Freedman R.R. Menopausal hot flashes: Mechanisms, endocrinology, treatment. J. Steroid Biochem. Mol. Biol. 2014;142:115–120. doi: 10.1016/j.jsbmb.2013.08.010.
    1. Tao M., Teng Y., Shao H., Wu P., Mills E.J. Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: A systematic review and meta-synthesis. PLoS ONE. 2011;6:e24661. doi: 10.1371/journal.pone.0024661.
    1. Marjoribanks J., Farquhar C., Roberts H., Lethaby A., Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2017;1:CD004143. doi: 10.1002/14651858.CD004143.pub5.
    1. French L.M., Smith M.A., Holtrop J.S., Holmes-Rovner M. Hormone therapy after the Women’s Health Initiative: A qualitative study. BMC Fam. Pract. 2006;7:61. doi: 10.1186/1471-2296-7-61.
    1. Schonberg M.A., Davis R.B., Wee C.C. After the women’s health initiative: Decision making and trust of women taking hormone therapy. Women’s Health Issues. 2005;15:187–195. doi: 10.1016/j.whi.2005.03.003.
    1. Nedrow A., Miller J., Walker M., Nygren P., Huffman L.H., Nelson H.D. Complementary and alternative therapies for the management of menopause-related symptoms: A systematic evidence review. Arch. Intern. Med. 2006;166:1453–1465. doi: 10.1001/archinte.166.14.1453.
    1. Wong V.C., Lim C.E., Luo X., Wong W.S. Current alternative and complementary therapies used in menopause. Gynecol. Endocrinol. 2009;25:166–174. doi: 10.1080/09513590802549866.
    1. Mintziori G., Lambrinoudaki I., Goulis D.G., Ceausu I., Depypere H., Erel C.T., Pérez-López F.R., Schenck-Gustafsson K., Simoncini T., Tremollieres F., et al. EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. Maturitas. 2015;81:410–413. doi: 10.1016/j.maturitas.2015.04.009.
    1. Booth N.L., Piersen C.E., Banuvar S., Geller S.E., Shulman L.P., Farnsworth N.R. Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: A literature review. Menopause. 2006;13:251–264. doi: 10.1097/01.gme.0000198297.40269.f7.
    1. Lemežienė N., Padarauskas A., Butkutė B., Cesevičienė J., Taujenis L., Norkevičienė E. The concentration of isoflavones in red clover (Trifolium pratense L.) at flowering stage. Zemdirb.-Agric. 2015;102:443–448. doi: 10.13080/z-a.2015.102.057.
    1. Tolleson W.H., Doerge D.R., Churchwell M.I., Marques M.M., Roberts D.W. Metabolism of biochanin A and formononetin by human liver microsomes in vitro. J. Agric. Food Chem. 2002;50:4783–4790. doi: 10.1021/jf025549r.
    1. Liu J., Burdette J.E., Xu H., Gu C., van Breemen R.B., Bhat K.P., Booth N., Constantinou A.I., Pezzuto J.M., Fong H.H., et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agric. Food Chem. 2001;49:2472–2479. doi: 10.1021/jf0014157.
    1. Morito K., Aomori T., Hirose T., Kinjo J., Hasegawa J., Ogawa S., Inoue S., Muramatsu M., Masamune Y. Interaction of phy-toestrogens with estrogen receptors alpha and beta (II) Biol. Pharm. Bull. 2002;25:48–52. doi: 10.1248/bpb.25.48.
    1. Welch V., Petticrew M., Petkovic J., Moher D., Waters E., White H., Tugwell P., Atun R., Awasthi S., Barbour V., et al. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): Explanation and elaboration. J. Clin. Epidemiol. 2016;70:68–89. doi: 10.1016/j.jclinepi.2015.09.001.
    1. Kupperman H.S., Blatt M.H., Wiesbader H., Filler W. Comparative clinical evaluation of estrogenic preparations by the meno-pausal and amenorrheal indices. J. Clin. Endocrinol. Metab. 1953;13:688–703. doi: 10.1210/jcem-13-6-688.
    1. Greene J.G. A factor analytic study of climacteric symptoms. J. Psychosom. Res. 1976;20:425–430. doi: 10.1016/0022-3999(76)90005-2.
    1. Schneider H.P., Heinemann L.A., Rosemeier H.P., Potthoff P., Behre H.M. The Menopause Rating Scale (MRS): Reliability of scores of menopausal complaints. Climacteric. 2000;3:59–64. doi: 10.3109/13697130009167600.
    1. Higgins J.P., Altman D.G., Gøtzsche P.C., Jüni P., Moher D., Oxman A.D., Savović J., Schulz K.F., Weeks L., Sterne J.A.C., et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:5928. doi: 10.1136/bmj.d5928.
    1. Follmann O., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. Epidemiol. 1999;45:769–773. doi: 10.1016/0895-4356(92)90054-Q.
    1. Higgins J.P.T., Deeks J.J. Selecting studies and collecting data. In: Higgins J.P.T., Green S., editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; John Wiley & Sons; Chichester, UK: 2008. pp. 172–178.
    1. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin. Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2.
    1. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21:1539–1558. doi: 10.1002/sim.1186.
    1. Knight D.C., Howes J.B., Eden J.A. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric. 1999;2:79–84. doi: 10.3109/13697139909025570.
    1. Baber R.J., Templeman C., Morton T., Kelly G.E., West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric. 1999;2:85–92. doi: 10.3109/13697139909025571.
    1. Jeri A.R. The use of an isoflavone supplement to relieve hot flashes. Female Patient. 2002;27:35–37.
    1. van de Weijer P.H., Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas. 2002;42:187–193. doi: 10.1016/S0378-5122(02)00080-4.
    1. Tice J.A., Ettinger B., Ensrud K., Wallace R., Blackwell T., Cummings S.R. Phytoestrogen supplements for the treatment of hot flashes: The isoflavone clover extract (ICE) study: A randomized controlled trial. JAMA. 2003;290:207–214. doi: 10.1001/jama.290.2.207.
    1. Atkinson C., Warren R.M.L., Sala E., Dowsett M., Dunning A.M., Healey C.S., Runswick S., Day N.E., Bingham S.A. Red clover-derived isoflavones and mammographic breast density: A double-blind, randomized, placebo-controlled trial [ISRCTN42940165] Breast Cancer Res. 2004;6:R170–R179. doi: 10.1186/bcr773.
    1. Hidalgo L.A., Chedraui P.A., Morocho N., Ross S., Miguel G.S. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: A randomized, double-blind, placebo-controlled study. Gynecol. Endocrinol. 2005;21:257–264. doi: 10.1080/09513590500361192.
    1. del Giorno C., Fonseca A.M., Bagnoli V.R., Assis J.S., Soares J.M., Jr., Baracat E.C. Effects of Trifolium pratense on the climacteric and sexual symptoms in postmenopause women. Rev. Assoc. Med. Bras. 2010;56:558–562.
    1. Lipovac M., Chedraui P., Gruenhut C., Gocan A., Kurz C., Neuber B., Imhof M. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. Gynecol. Endocrinol. 2012;28:203–207. doi: 10.3109/09513590.2011.593671.
    1. Clifton-Bligh P.B., Nery M.L., Cliftonbligh R.J., Visvalingam S., Fulcher G.R., Byth K., Baber R. Red clover isoflavones enriched with formononetin lower serum LDL cholesterol—A randomized, double-blind, placebo-controlled study. Eur. J. Clin. Nutr. 2015;69:134–142. doi: 10.1038/ejcn.2014.207.
    1. Shakeri F., Taavoni S., Goushegir A., Haghani H. Effectiveness of red clover in alleviating menopausal symptoms: A 12-week randomized, controlled trial. Climacteric. 2015;18:568–573. doi: 10.3109/13697137.2014.999660.
    1. Lambert M.N.T., Thorup A.C., Hansen E.S.S., Jeppesen P.B. Combined red clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms. PLoS ONE. 2017;12:e0176590. doi: 10.1371/journal.pone.0176590.
    1. Myers S.P., Vigar V. Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80 mg in the treatment of menopausal hot flushes: A systematic review and meta-analysis. Phytomedicine. 2017;24:141–147. doi: 10.1016/j.phymed.2016.12.003.
    1. Coon J.T., Pittler M.H., Ernst E. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: A systematic review and meta-analysis. Phytomedicine. 2007;14:153–159. doi: 10.1016/j.phymed.2006.12.009.
    1. Ghazanfarpour M., Sadeghi R., Roudsari R.L., Khorsand I., Khadivzadeh T., Muoio B. Red clover for treatment of hot flashes and menopausal symptoms: A systematic review and meta-analysis. J. Obstet. Gynaecol. 2016;36:301. doi: 10.3109/01443615.2015.1049249.
    1. Lethaby A., Marjoribanks J., Kronenberg F., Roberts H., Eden J., Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst. Rev. 2013;12:CD001395. doi: 10.1002/14651858.CD001395.pub4.
    1. Nelson H.D., Vesco K.K., Haney E., Fu R., Nedrow A., Miller J., Nicolaidis C., Walker M., Humphrey L. Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. JAMA. 2006;295:2057–2071. doi: 10.1001/jama.295.17.2057.
    1. Franco O.H., Chowdhury R., Troup J., Voortman T., Kunutsor S., Kavousi M., Oliver-Williams C., Muka T. Use of plant-based therapies and menopausal symptoms: A systematic review and meta-analysis. JAMA. 2016;315:2554–2563. doi: 10.1001/jama.2016.8012.
    1. Krebs E.E., Ensrud K.E., Macdonald R., Wilt T.J. Phytoestrogens for treatment of menopausal symptoms: A systematic review. Obstet. Gynecol. 2004;104:824–836. doi: 10.1097/01.AOG.0000140688.71638.d3.
    1. Gartoulla P., Han M.M. Red clover extract for alleviating hot flushes in postmenopausal women: A meta-analysis. Maturitas. 2014;79:58–64. doi: 10.1016/j.maturitas.2014.06.018.
    1. Li L., Xu L., Wu J., Dong L., Lv Y., Zheng Q. Quantitative analysis of placebo response and factors associated with menopausal hot flashes. Menopause. 2017;24:932–937. doi: 10.1097/GME.0000000000000858.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren